Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects

Author:Sevinsky, Heather   Rozakis, Rachel   Nepomuceno, Tracy   Malatesta, Jo Ann   Awsare, Bharat   Ashbrenner, Eric   Kaplita, Stephen   Gentile, Kimberly   Hussey, Elizabeth   Qureshi, Irfan   Coric, Vladimir   Bertz, Richard   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.006  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven , CT  Allucent, Cary, NC  Biohaven Pharmaceuticals, Inc, New Haven, CT  Certara, Inc, Princeton, NJ  Biohaven Pharmaceuticals, Inc, New Haven, CT  Biohaven Pharmaceuticals, Inc, Cheshire, CT  

Inhibition of MicroRNA-183 Attenuates Pathological TDP-43 Aggregation via SQSTM1/p62 in ALS

Author:Lu, Liang   Kim, Han-Cheon   Zhang, Yan   King, Peter   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.007  

Author Institution:BCM, BELLAIRE, TX  UTH, Houston, TX  BCM, Houston, TX  UAB, Birmingham, AL  

Pre-clinical Antisense Oligonucleotide Treatment of CMT2E in a Human Induced Pluripotent Stem Cell (iPSC)-derived Motor Neuron Model

Author:Medina, Jessica   Rebelo, Adriana   Jacobs, Elizabeth   Danzi, Matt   Zuchner, Stephan   Saporta, Mario   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.008  

Author Institution:University of Miami, MIAMI, FL  University of Miami School of Medicine, Miami, FL  

Potential ASO-based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S

Author:Tyner, Christina   Smieszek, Sandra   Przychodzen, Bart   Johnson, Caroline   Polymeropoulos, Christos   Birznieks, Gunther   Polymeropoulos, Mihael   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.009  

Author Institution:Vanda Pharmaceuticals Inc., Washington, DC  Vanda Pharmaceuticals Inc., Washington, DC, DC  

Polygenic Resistance to Blood Pressure Treatment and Stroke Risk

Author:Huo, Shufan   Rivier, Cyprien   Clocchiatti-Tuozzo, Santiago   Renedo, Daniela   Zhao, Hongyu   De Havenon, Adam   Sheth, Kevin   Falcone, Guido   

Session Name:S6: Stroke Pathophysiology and Prediction  

Topic:Cerebrovascular Disease and Interventional Neurology  

Program Number:S6.001  

Author Institution:Yale University, New Haven, CT  Yale University, Department of Neurology, New Haven, CT  Yale University Division of Neuro and Critical Care, New Haven, CT  Yale School of Medicine, New Haven, CT